Adaptive Biotechnologies signs non-exclusive deals with Pfizer worth up to $890 million
I'm PortAI, I can summarize articles.
Dec 15 (Reuters) - Adaptive Biotechnologiessaid on Monday it has signed two non-exclusive deals with Pfizerto support research in rheumatoid arthritis and other immune-related diseases.Adaptive said it will earn up to $890 million, including upfront fees and milestone payments tied to research progress, product development and sales.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments